Comparative effects of statin and fibrate on nitric oxide bioactivity and matrix metalloproteinase in hyperlipidemia

Objective: Because the lipoprotein effects of statin and fibric acid derivatives therapies differ, we studied the effects of these therapies in patients with hyperlipidemia on lipoproteins, vasomotor function, and plaque stability. Methods: We administered simvastatin, 20 mg daily, to 27 patients wi...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cardiology 2004-11, Vol.97 (2), p.239-244
Main Authors: Koh, Kwang Kon, Ahn, Jeong Yeal, Jin, Dong Kyu, Han, Seung Hwan, Kim, Hyung Sik, Choi, In Suck, Ahn, Tae Hoon, Shin, Eak Kyun, Jeong, Euy-Myoung
Format: Article
Language:English
Subjects:
Atherosclerosis
Atherosclerosis (general aspects, experimental research)
Biological and medical sciences
Blood and lymphatic vessels
Brachial Artery - drug effects
Cardiology. Vascular system
Coronary Artery Disease - blood
Coronary Artery Disease - complications
Disorders of blood lipids. Hyperlipoproteinemia
Female
Fenofibrate - pharmacology
Fibrate
HMG-CoA reductase inhibitor
Humans
Hyperlipidemia
Hyperlipidemias - blood
Hyperlipidemias - complications
Hypolipidemic Agents - pharmacology
Lipids - blood
Male
Matrix Metalloproteinases - blood
Matrix Metalloproteinases - drug effects
Medical sciences
Metabolic diseases
Middle Aged
Nitrates - blood
Nitric oxide
Nitric Oxide - metabolism
Plaque stability
Simvastatin - pharmacology
Tissue Inhibitor of Metalloproteinase-1 - blood
Tissue Inhibitor of Metalloproteinase-1 - drug effects
Tumor Necrosis Factor-alpha - drug effects
Tumor Necrosis Factor-alpha - metabolism
Vasodilation - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: Because the lipoprotein effects of statin and fibric acid derivatives therapies differ, we studied the effects of these therapies in patients with hyperlipidemia on lipoproteins, vasomotor function, and plaque stability. Methods: We administered simvastatin, 20 mg daily, to 27 patients with hypercholesterolemia and coronary artery disease, or fenofibrate, 200 mg daily, to 27 patients with pure hypertriglyceridemia during 8 weeks. Results: As expected, simvastatin significantly lowered total cholesterol and low-density lipoprotein cholesterol (LDL-C) more, and fenofibrate decreased triglyceride and increased high-density lipoprotein cholesterol (HDL-C) more than either therapy. Simvastatin and fenofibrate significantly improved the percent flow-mediated dilator response to hyperemia by 183±41% and by 30±7%, respectively (each P
ISSN:0167-5273
1874-1754
DOI:10.1016/j.ijcard.2003.09.007